Long Terms Follow-Up of the Randomized MetaspHER Study Comparing Intravenous Versus Subcutaneous Trastuzumab in Patients' With HER2-Positive Metastatic Breast Cancer.
Fiche publication
Date publication
juin 2023
Journal
Clinical breast cancer
Auteurs
Membres identifiés du Cancéropôle Est :
Pr PIVOT Xavier, Dr SPAETH Dominique, Dr JOUANNAUD Christelle
Tous les auteurs :
Pivot X, Spano JP, Espie M, Jouannaud C, Pottier V, Moreau L, Extra JM, Lortholary A, Rivera P, Spaeth D, Mouri Z, Tariket F, Dupin J, Berthois A, Ionescu-Goga M, Ferhat A, Cottu P, Gligorov J
Lien Pubmed
Résumé
The subcutaneous (H-SC) formulation of trastuzumab was demonstrated to be as effective and safe as intravenous (H-IV) and highly preferred by patients in early breast cancer. The present randomized MetaspHER trial (NCT01810393) has been the first study assessing patient's preference in metastatic setting and we report the final analysis with long term follow-up.
Mots clés
Preference, Herceptin
Référence
Clin Breast Cancer. 2023 06 20;: